Plandai Biotechnology's Human Clinical Trials Offer Significant Proof of Concept
March 26 2014 - 9:00AM
Marketwired
Plandai Biotechnology's Human Clinical Trials Offer Significant
Proof of Concept
NEW YORK, NY--(Marketwired - Mar 26, 2014) - What may have been
lost in Plandaí Biotechnology's (OTCQB: PLPL) recently reported
results from its human clinical trial to test the anti-aging
properties of Phytofare™, is that the "statistically significant"
results are themselves extremely significant to the future of the
company. First and foremost, the results delivered in this human
trial using Plandaí's Phytofare™ Catechin Complex show "proof of
concept," and for investors, that proof should turn out to be no
small thing when it comes to the future success of this
company.
Proof of concept is vital to any new product, and it means that
the company's claims of higher bioavailability with their Phytofare
products are validated on the ultimate stage -- a human
clinical trial. These results could lead Plandaí's distribution
partners to use Phytofare™ Catechin Complex in wide range of
cosmetic products from moisturizers to shampoos to hand and face
creams among many others. The more products these distributors can
put Phytofare™ Catechin Complex into, the more product Plandaí can
deliver to partners.
According to Plandaí, the data from this double-blind study
showed that Phytofare yielded "statistically significant" results
when compared to a baseline product. The trial involved 35
Caucasian women who applied 2 topical creams daily, one of which
contained Plandaí's Phytofare™, to patches of their skin. The women
then had their skin tested for scaling and roughness, skin
hydration, and skin elasticity at 14, 28, and 42 days.
In the tested areas, the study showed that the addition of
Phytofare:
- Improved skin roughness by as much as 15% at 28 days
- Reduced scaliness of the top layer of skin by 20%
Both of these measures were deemed "statistically significant"
by Professor Banie Boneschans of North West University in
Potchefstroom, South Africa, one of the leading research
universities on the continent, who conducted the trial.
Additionally the study showed:
- Phytofare increased skin hydration by 15% at both 28 and 42
days, compared to .9% and 7.8% for the base product. The study
pointed out that skin hydration improved significantly at 28 days
and maintained that level throughout the study.
- An average improvement in skin elasticity of 1% at 42 days
What Plandaí has shown in this trial is very good news for
investors. Any successful human clinical trial should be viewed as
significant, and these results should impress the company's
partners significantly.
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and
Content Development. It offers a platform for corporate stories to
unfold through the media with Reports, Interviews and Articles.
SMMG is compensated for Plandaí articles, reports and interviews by
a third party who reserves the right to sell securities at any time
before, during, or after the publication of this article. To date,
SMMG has received total compensation of $36,290, for content
related to Plandaí. For more information and to read full
disclaimers and disclosures:
www.stockmarketmediagroup.com/disclaimer.
Contact: Stock Market Media Group Email Contact
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Oct 2023 to Oct 2024